Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Detalle, Laurent, Stohr, Thomas, Palomo, Concepción, Piedra, Pedro A., Gilbert, Brian E., Mas, Vicente, Millar, Andrena, Power, Ultan F., Stortelers, Catelijne, Allosery, Koen, Melero, José A., Depla, Erik
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2015
Soggetti:
Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704182/
https://ncbi.nlm.nih.gov/pubmed/26438495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01802-15
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi